The best weight loss pill for men is not a one-size-fits-all answer — the most appropriate licensed medicine depends on your BMI, medical history, and overall health profile. In the UK, weight loss treatments are regulated by the MHRA and must be prescribed or supplied through authorised channels. Options include orlistat, semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Mounjaro), and naltrexone/bupropion (Mysimba). This guide explains how each medicine works, what the clinical evidence shows, potential side effects, and how to access treatment safely through the NHS or a regulated private provider.

Weight Loss Medicines Available to Men in the UK

The main licensed weight loss medicines available to men in the UK are orlistat, semaglutide (Wegovy), liraglutide (Saxenda), tirzepatide (Mounjaro), and naltrexone/bupropion (Mysimba), all regulated by the MHRA and only legally available through authorised channels.

In the UK, weight loss medicines are regulated by the Medicines and Healthcare products Regulatory Agency (MHRA) and are only legally available when prescribed or supplied through authorised channels. There is no single 'best weight loss pill for men' — the most appropriate treatment depends on an individual's medical history, body mass index (BMI), and overall health profile.

Currently, the main licensed weight loss medicines available in the UK include:

• Orlistat (Xenical / Alli) — available on prescription or, at a lower dose (60 mg), over the counter from pharmacies

• Semaglutide (Wegovy) — a once-weekly injectable medicine approved by the MHRA for weight management and recommended by NICE (TA875); it should be prescribed within a specialist weight management service. Note: Ozempic is a different semaglutide product licensed for type 2 diabetes, not for weight management

• Liraglutide (Saxenda) — another injectable option, NICE-approved (TA664) for obesity management within specialist weight management services

• Tirzepatide (Mounjaro) — approved by the MHRA for weight management in adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above in the presence of at least one weight-related comorbidity; NHS availability is subject to ongoing NICE guidance and local integrated care board (ICB) commissioning

• Naltrexone/bupropion (Mysimba) — a licensed oral combination tablet available in the UK; there is currently no positive NICE technology appraisal for NHS use in England, but it may be available through private prescribing following a clinical assessment

It is important to note that many products marketed online as 'weight loss pills for men' — including herbal supplements, fat burners, and unlicensed tablets — are not regulated medicines. These products may be ineffective, unsafe, or counterfeit. The NHS and MHRA strongly advise against purchasing weight loss products from unverified online sources. Men seeking medical support for weight loss should always consult a GP, pharmacist, or registered weight management service.

How These Treatments Work and Who They Are Suitable For

Each medicine works differently: orlistat blocks fat absorption, GLP-1 agonists reduce appetite via brain receptors, tirzepatide acts on both GLP-1 and GIP receptors, and naltrexone/bupropion modulates the hypothalamic appetite pathway. Suitability depends on BMI thresholds and individual comorbidities.

Each licensed weight loss medicine works through a distinct pharmacological mechanism, and suitability varies between individuals.

Orlistat works by inhibiting pancreatic and gastric lipases — enzymes responsible for breaking down dietary fat in the gut. Approximately one-third of ingested fat passes through the body unabsorbed, reducing overall calorie intake. It is generally suitable for adults with a BMI of 28 kg/m² or above when accompanied by weight-related risk factors (such as type 2 diabetes or hypertension), or a BMI of 30 kg/m² or above.

Semaglutide (Wegovy) and liraglutide (Saxenda) are glucagon-like peptide-1 (GLP-1) receptor agonists. They mimic the action of the naturally occurring GLP-1 hormone, which regulates appetite and food intake by acting on receptors in the brain. These medicines slow gastric emptying, promote a feeling of fullness, and reduce hunger signals. NICE guidance recommends Wegovy (TA875) for adults with a BMI of at least 35 kg/m² alongside at least one weight-related comorbidity, or a BMI of 30–34.9 kg/m² in certain circumstances. Lower BMI thresholds apply for people from some minority ethnic backgrounds, in line with NICE recommendations. Both Wegovy and Saxenda should be prescribed within a specialist weight management service and are typically NHS-funded for up to two years, subject to eligibility criteria and early response thresholds.

Tirzepatide (Mounjaro) acts on both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors, offering a dual mechanism. Its UK licence for weight management covers adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity. NHS access depends on current NICE guidance and local ICB commissioning decisions, which are evolving.

Naltrexone/bupropion (Mysimba) modulates the pro-opiomelanocortin (POMC) pathway in the hypothalamus, reducing appetite and food cravings. It is licensed for adults with a BMI of 30 kg/m² or above, or 27 kg/m² or above with at least one weight-related comorbidity. Key contraindications include uncontrolled hypertension, a history of seizure disorder, current or recent use of monoamine oxidase inhibitors (MAOIs), and concurrent opioid use or opioid dependence. It is not currently recommended by NICE for NHS use in England but may be prescribed privately.

None of these medicines are suitable for everyone. Men with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2) should not use GLP-1 receptor agonists. All of these medicines are contraindicated during pregnancy and breastfeeding. A thorough medical assessment is always required before starting any treatment.

Effectiveness: What the Clinical Evidence Shows

Semaglutide 2.4 mg (Wegovy) has the strongest evidence, with the STEP 1 trial showing approximately 14.9% mean body weight loss over 68 weeks; tirzepatide showed up to 20.9% in SURMOUNT-1, while orlistat produces more modest results of around 3–5 kg above placebo.

Clinical evidence for licensed weight loss medicines is robust, though results vary between individuals and are consistently strongest when combined with dietary and lifestyle changes.

Orlistat has been shown in clinical trials to produce an average weight loss of approximately 3–5 kg more than placebo over 12 months. While modest, this can be clinically meaningful when sustained alongside dietary modification.

Liraglutide 3.0 mg (Saxenda) demonstrated a mean weight loss of approximately 5–8% of body weight at 56 weeks in the SCALE Obesity and Prediabetes trial, compared with approximately 2% in the placebo group.

Semaglutide 2.4 mg (Wegovy) has demonstrated considerably greater efficacy. The STEP 1 trial, published in the New England Journal of Medicine (2021), found that participants lost an average of 14.9% of their body weight over 68 weeks, compared with 2.4% in the placebo group. This represents a significant advance in pharmacological weight management.

Tirzepatide has shown substantial results in the SURMOUNT-1 trial, with participants achieving up to approximately 20.9% mean body weight reduction at the highest dose. Whilst these are notable outcomes, they generally remain below the typical weight loss achieved with bariatric surgery, and individual responses vary considerably.

Naltrexone/bupropion (Mysimba) produced mean weight loss of approximately 5–9% in the COR clinical trial programme, depending on the trial and analysis.

It is important to understand that:

• Weight loss medicines are not a permanent cure for obesity

• Weight regain is common after stopping treatment

• On the NHS, GLP-1 medicines for weight management (such as Wegovy) are typically funded for up to two years, subject to continuation criteria including an adequate early response to treatment

• Individual responses vary considerably

NICE and NHS guidance emphasises that these medicines should be used as part of a comprehensive weight management programme, not as standalone solutions. Men should have realistic expectations and discuss likely outcomes with a clinician before starting any pharmacological treatment.

Risks, Side Effects and Safety Considerations

GLP-1 medicines most commonly cause nausea, vomiting, and diarrhoea, while orlistat causes gastrointestinal side effects including oily stools; serious but rare risks include pancreatitis, gallbladder disease, and — for naltrexone/bupropion — seizures and raised blood pressure.

Experiencing these side effects? Our pharmacists can help you navigate them →

All licensed weight loss medicines carry potential risks and side effects, and men should be fully informed before commencing treatment.

Orlistat commonly causes gastrointestinal side effects, particularly when high-fat meals are consumed. These include:

• Oily or fatty stools

• Frequent or urgent bowel movements

• Flatulence and abdominal discomfort

• Faecal incontinence in some cases

Orlistat can also reduce the absorption of fat-soluble vitamins (A, D, E, and K), so a daily multivitamin taken at a separate time to the medication is often recommended. Important interactions include: reduced ciclosporin absorption (co-administration should be avoided or carefully managed); reduced anticoagulant effect of warfarin (INR should be monitored closely); and reduced absorption of levothyroxine (doses should be separated by several hours). Rarely, orlistat has been associated with severe liver injury — men should stop taking it and seek prompt medical advice if they develop jaundice, dark urine, or abdominal pain. There is also a risk of oxalate nephropathy, particularly in individuals with pre-existing chronic kidney disease.

GLP-1 receptor agonists (semaglutide, liraglutide) and the dual GLP-1/GIP agonist tirzepatide most commonly cause nausea, vomiting, diarrhoea, and constipation, particularly during dose escalation. These effects often improve over time. Additional risks include:

Not sure if this is normal? Chat with one of our pharmacists →

• Gallbladder disease and gallstones (cholelithiasis): Men should seek medical advice if they develop right upper quadrant pain, nausea, or jaundice

• Pancreatitis: Rare but serious; seek urgent medical attention for severe or persistent abdominal pain

• Worsening of diabetic retinopathy: Men with diabetes who have pre-existing retinopathy should be monitored carefully

• Thyroid C-cell tumours: Based on animal studies, a theoretical risk exists; these medicines are contraindicated in individuals with a personal or family history of medullary thyroid carcinoma or MEN2, though this risk has not been confirmed in humans

Naltrexone/bupropion (Mysimba) can increase blood pressure and heart rate, and is associated with a risk of seizures (particularly at higher doses or in susceptible individuals), insomnia, dry mouth, headache, and psychiatric effects including mood changes. It must not be used with MAOIs or in people taking opioid medicines.

Men should seek urgent medical attention (call 999) if they experience:

• Signs of a severe allergic reaction (widespread rash, swelling of the face or throat, difficulty breathing)

• Severe chest pain or acute breathing difficulties

Men should contact their GP or NHS 111 promptly if they experience:

• Severe or persistent abdominal pain (possible pancreatitis or gallbladder disease)

• Jaundice or dark urine (possible liver injury)

• Significant or persistent changes in mood, or thoughts of self-harm

• Unexplained rapid or irregular heartbeat

The MHRA monitors the safety of all licensed weight loss medicines through its Yellow Card pharmacovigilance scheme. Men are encouraged to report any suspected side effects via the MHRA Yellow Card website at yellowcard.mhra.gov.uk.

How to Access Weight Loss Treatment Through the NHS or a Pharmacy

Orlistat 60 mg is available over the counter from pharmacies; injectable GLP-1 medicines require a GP referral to a specialist weight management service on the NHS, or a clinical assessment through a CQC-registered private provider.

Access to weight loss medicines in the UK depends on the specific treatment and the individual's clinical circumstances.

Via the NHS: A GP can prescribe orlistat for eligible patients and may refer individuals to specialist weight management services for injectable treatments such as semaglutide or tirzepatide. NICE guidance (TA875) specifies that Wegovy should be prescribed within a specialist weight management service and is typically NHS-funded for up to two years, subject to eligibility and early response criteria. NHS England has been rolling out access through integrated care boards (ICBs) on a phased basis. Saxenda (liraglutide) is similarly restricted to specialist services under NICE TA664. Tirzepatide (Mounjaro) NHS availability for weight management is subject to current NICE guidance and local ICB commissioning decisions, which continue to evolve. Waiting times for specialist services can be lengthy in some areas.

It is also worth noting that GLP-1 medicines have been subject to intermittent supply constraints. Men should follow current NHS and MHRA guidance on availability and not stockpile or source medicines outside regulated channels.

Via pharmacies: Lower-dose orlistat (60 mg, branded as Alli) is available over the counter from registered pharmacies without a prescription, following a consultation with the pharmacist to confirm suitability. Some community pharmacies also offer weight management consultations as part of NHS or private services.

Via private providers: A number of regulated online clinics and private weight management services offer prescriptions for GLP-1 medicines following a clinical assessment. Men using these services should ensure the provider is registered with the Care Quality Commission (CQC) in England, Healthcare Improvement Scotland (HIS) in Scotland, or Healthcare Inspectorate Wales (HIW) in Wales, and that prescriptions are issued by an appropriately registered independent prescriber (for example, a GMC-, GPhC-, or NMC-registered prescriber) and dispensed by a GPhC-registered pharmacy.

To verify that an online pharmacy is legitimate, check that it appears on the General Pharmaceutical Council (GPhC) register at pharmacyregulation.org. The EU common logo is no longer used as a verification mark for pharmacies in Great Britain.

Men are strongly advised to avoid purchasing weight loss medicines from unregulated websites. The MHRA has warned that counterfeit versions of injectable weight loss medicines are in circulation and may pose serious health risks.

Lifestyle Changes That Support Long-Term Weight Management

NICE guidance consistently states that weight loss medicines must complement lifestyle changes, including a structured calorie deficit, at least 150 minutes of moderate aerobic activity per week, and behavioural support — not replace them.

Medicines alone are rarely sufficient for sustainable weight loss. Clinical guidelines from NICE consistently emphasise that pharmacological treatment should complement — not replace — meaningful lifestyle modification.

Dietary changes form the cornerstone of any effective weight management plan. NICE obesity guidance supports a structured calorie deficit of approximately 600 kcal per day below estimated requirements, rather than extreme restriction. Practical approaches include:

• Reducing ultra-processed food and high-sugar drink consumption

• Increasing intake of vegetables, wholegrains, lean protein, and healthy fats

• Eating regular meals to support appetite regulation

• Being mindful of portion sizes and alcohol intake, which is a significant source of hidden calories for many men

Physical activity is equally important, both for weight management and broader cardiovascular and metabolic health. The UK Chief Medical Officers' Physical Activity Guidelines recommend at least 150 minutes of moderate-intensity aerobic activity per week, alongside muscle-strengthening activities on two or more days. Resistance training is particularly beneficial for men, as it helps preserve lean muscle mass during weight loss.

Behavioural support — including cognitive behavioural approaches, goal-setting, and self-monitoring — has strong evidence behind it. NHS weight management programmes, delivered through Tier 2 (community-based) and Tier 3 (specialist multidisciplinary) services, incorporate these elements alongside dietary and physical activity guidance. GPs can advise on local referral pathways to these services.

Sleep and stress management are often overlooked but clinically relevant. Poor sleep and chronic stress are associated with elevated cortisol levels, increased appetite, and a preference for calorie-dense foods. Addressing these factors can meaningfully support weight management efforts over the long term.

Men who are struggling with their weight are encouraged to speak openly with their GP, who can coordinate access to the most appropriate combination of support, including referral to structured NHS weight management programmes where eligible.

Frequently Asked Questions